Retatrutide, an obesity drug in development at U.S. pharmaceutical giant Eli Lilly, produced average weight loss of 25% over 80 weeks among patients receiving the highest dose in a late-stage clinical trial. A group of patients extended treatment to 104 weeks, although the available results do not provide an average weight-loss figure for that period.